Company Neurocrine Biosciences, Inc. Deutsche Boerse AG
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.8 EUR | -1.35% |
|
+3.10% | +13.38% |
Jul. 09 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
Jul. 03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
Business Summary
Number of employees: 1,448
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Eiry Roberts
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-01-07 |
Bill Wilson
COO | Chief Operating Officer | - | 96-08-31 |
Chief Tech/Sci/R&D Officer | 65 | 92-12-31 | |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Todd Tushla
IRC | Investor Relations Contact | - | - |
Ingrid Delaet
LAW | General Counsel | 58 | 20-12-31 |
David Boyer
PRN | Corporate Officer/Principal | 44 | 19-09-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Christine Poon
BRD | Director/Board Member | 71 | 23-07-10 |
Chairman | 75 | 10-02-07 | |
Richard Pops
BRD | Director/Board Member | 62 | 98-03-31 |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 98-03-31 |
Shalini Sharp
BRD | Director/Board Member | 49 | 20-02-02 |
Johanna Mercier
BRD | Director/Board Member | 54 | 21-04-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 100,637,227 | 98,821,834 ( 98.20 %) | 0 | 98.20 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. 15.77% | 8,575,316 | 15.77% | 67,830,750 $ |
Company contact information
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
92130, San Diego
+858 617 7600
http://www.neurocrine.com![address Neurocrine Biosciences, Inc.(NB3)](https://cdn.zonebourse.com/static/address/440377.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
-47.10% | 14.65B | |
+54.50% | 14.43B | |
+151.63% | 12.49B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock
- Company Neurocrine Biosciences, Inc.